Cleveland, OHNCT05312801Now EnrollingIRB Ready

Lymphoma, Non-Hodgkin Lymphoma, B-Cell Clinical Trial in Cleveland, OH

Access cutting-edge lymphoma, non-hodgkin lymphoma, b-cell treatment through this clinical trial at a research site in Cleveland. Study-provided care at no cost to qualified participants.

Sponsored by Luminary Therapeutics

Quick Self-Assessment

See if you qualify for this Cleveland location

Preparing your pre-screening questions…

Expert Care in Cleveland

Access lymphoma, non-hodgkin lymphoma, b-cell specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related lymphoma, non-hodgkin lymphoma, b-cell treatment provided free

Apply for This Cleveland Location

Check if you qualify for this lymphoma, non-hodgkin lymphoma, b-cell clinical trial in Cleveland, OH

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to Cleveland

    Convenient for OH residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit Cleveland site if eligible
  4. 4Begin participation

About This Lymphoma, Non-Hodgkin Lymphoma, B-Cell Study in Cleveland

Therapy with chimeric antigen receptor T (CAR-T) cells has demonstrated activity against refractory lymphoma, however not all tumors respond or remain in response to CD19 targeted CAR-T cells. We posit that CAR-T cells expressing BAFF (BAFF CAR-T cells) can become another strategy to treat refractory lymphoma, even after relapse following cluster of differentiation antigen 19 (CD19) targeting CAR-T treatment. This phase 1 study will evaluate safe dose and provide initial signal of the activity of BAFF CAR-T cells against relapsed non-Hodgkin lymphoma using a single lymphodepletion regimen and using a BAFF CAR-T cell manufacturing process.

Sponsor: Luminary Therapeutics

Who Can Participate

Inclusion Criteria

Subjects must have histologically confirmed non-Hodgkin lymphoma relapsed after 2 or more lines of therapy or disease refractory to chemotherapy (defined as progressive disease or stable disease lasting ≤6 months, as best response to most recent chemotherapy regimen; or disease progression or recurrence ≤12 months after prior autologous stem cell transplantation (ASCT).
No evidence of central nervous system (CNS) lymphoma.
Male or female \> 18 years of age.
Eastern Cooperative Oncology Group Performance status ≤ 2.
At least one measurable lesion.
\>2 weeks since prior radiation therapy or systemic therapy at the time of leukapheresis.
Total bilirubin ≤ 1.5 mg/dL (except in patients with Gilbert's syndrome).
Aspartate aminotransferase/alanine transferase ≤ 2.5 X institutional upper limit of normal.
Serum creatinine \< 1.5 mg/dL.
Cardiac ejection fraction of \>50%, and no evidence of pericardial effusion, as determined by an echocardiogram.
Adequate pulmonary function as defined as pulse oximetry ≥ 92% on room air.
Subjects (or legal guardians) must have the ability to understand and the willingness to sign a written informed consent document.
For women of childbearing potential: agreement to remain abstinent (refrain from heterosexual intercourse) or use a contraceptive method with a failure rate of \< 1% per year during the treatment period and for at least 90 days after the BAFF CAR-T cell infusion.
For men: agreement to remain abstinent (refrain from heterosexual intercourse) or use contraceptive measures, and agreement to refrain from donating sperm.

Exclusion Criteria

ASCT within 6 weeks of informed consent.
History of allogeneic hematopoietic stem cell transplantation.
Active graft-versus-host disease.
Active central nervous system or meningeal involvement by lymphoma or leukemia.
Active malignancy, other than non-melanoma skin cancer or carcinoma in situ (e.g. cervix, bladder, breast).
Less than 28 days elapsed between prior treatment with investigational agent(s) and the day of lymphocyte collection.
New York Heart Association class IV congestive heart failure.
Cardiovascular disorders including unstable angina pectoris, clinically significant cardiac arrhythmias, myocardial infarction or stroke (including transient ischemic attack, or other ischemic event) within 6 months prior to registration.
Active infection requiring intravenous systemic treatment.
HIV seropositivity.
Pregnant or breastfeeding women.
Evidence of myelodysplasia or cytogenetic abnormality indicative of myelodysplasia on any bone marrow biopsy prior to initiation of therapy.
Serologic status reflecting active hepatitis B or C infection.
Patients with history of clinically relevant CNS pathology such as epilepsy, seizure disorders, paresis, aphasia, uncontrolled cerebrovascular disease, severe brain injuries, dementia and Parkinson's disease.
Subjects with uncontrolled intercurrent illness.
Known additional malignancies which require systemic treatment.
History of autoimmune disease with requirement of immunosuppressive medications (other than low dose steroids) within 6 months.

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Cleveland?

Yes, this clinical trial (NCT05312801) has an active research site in Cleveland, OH that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Lymphoma, Non-Hodgkin Lymphoma, B-Cell Treatment Options in Cleveland, OH

If you're searching for lymphoma, non-hodgkin lymphoma, b-cell treatment options in Cleveland, OH, this clinical trial (NCT05312801) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Cleveland research site is actively enrolling participants for this clinical trial. You'll receive care from experienced lymphoma, non-hodgkin lymphoma, b-cell specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all lymphoma, non-hodgkin lymphoma, b-cell clinical trials near you to find additional studies recruiting in your area.

More Lymphoma Trials in Cleveland, OH

See all lymphoma clinical trials recruiting in Cleveland — not just this study.

Browse Lymphoma Trials in Cleveland →

Browse More Trials by Condition

Lymphoma TrialsPulmonary Hypertension TrialsAll Conditions →

Ready to Join in Cleveland?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · Cleveland, OH